AIExome® Human Exome Panel V3 – Tumor is a version of AIExome® V3 specifically designed to detect tumor related mutations. In addition to the superior coverage of CDS region as AIExome® V3, AIExome® V3 – Tumor also covers important fusions, MSIs, HLA regions and tumor related genes.
Panel Number | T600V1ST |
Technical Platform | TargetSeq® Hybridization Capture Sequencing |
Coverage Size | 34.9 Mb |
Reference Database | RefSeq、MANE、CCDS etc. |
Reference Genome | GRCh38 (hg38) |
Coverage | CDS, HLA haplotypes, 641 tumor-related genes, 38 hotspot intron fusion regions, 15 MSIs |
Storage | <-70℃ |
Sequence Platform | Illumina / MGI |
Recommend Sequencing Read Length | PE150 |
Recommend Sequencing Data Size and Depth | 20Gb / 200X |
The AIExome® Human Exome Panel V3 product is available in 3 versions:
| CDS Region | Internal Reference QC SNPs | ClinVar | Mitochondria | SNP Backbone | Fusion | HLA | 641 Tumor-related Hotspot Genes | |
AIExome® V3 | ✓ | ✓ | ||||||
AIExome® V3 Inherit | ✓ | ✓ | ✓ | ✓ | ✓ | |||
AIExome® V3 Tomur | ✓ | ✓ | ✓ | ✓ | ✓ |
Covering over 99.9% of the CDS regions in major genetic databases.
MSI and TMB analysis enabled.
Increased probe density in regions of 641 tumor-related genes (especially mutation hotspots) to avoid missing detection of these key genes.
Upgraded TargetSeq One® v2.0 kits and workflow for easier handling and more robust experiment.Compatible with automated workflow to reduce manual operation and human errors.
Stable data reproducibility across different NGS platforms, with excellent data performance and outstanding cost-efficiency.
Test results of AIExome® V3 – Tumor (Illumina NovaSeq 6000, PE150, ~500X) using gDNA reference standard (Gene-Well, cat. GW-OGTM800) showed accurate and reproducible mutation calling of low frequency mutations.
| Gene | Variant | Expected allelic frequency (%) | Reported allelic frequency (%) | |
| Sample 1 | Sample 2 | |||
EGFR | L858R | 1.0% | 0.5% | 0.5% |
KRAS | A146T | 1.0% | 0.8% | 0.9% |
NRAS | Q61K | 1.0% | 1.0% | 0.4% |
EGFR | T790M | 2.0% | 1.6% | 1.5% |
EGFR | ΔE746_A750 | 2.0% | 0.9% | 1.6% |
FLT3 | ΔI836 | 2.0% | 1.9% | 1.6% |
KIT | D816V | 2.0% | 2.1% | 2.5% |
KRAS | G12D | 2.0% | 1.9% | 1.9% |
EGFR | V769_D770insASV | 3.0% | 2.1% | 1.6% |
EGFR | G719S | 4.0% | 3.3% | 2.9% |
KRAS | G13D | 4.0% | 3.2% | 3.2% |
BRAF | V600E | 7.0% | 5.2% | 4.8% |
PIK3CA | H1047R | 7.0% | 6.7% | 7.5% |
Test results of AIExome® V3 – Tumor (Illumina NovaSeq 6000, PE150, ~500X) using FFPE reference standard (Gene-Well, cat. GW-OGSM003) showed accurate and reproducible mutation calling of low frequency mutations.
| Gene | Variant | Expected allelic frequency (%) | Reported allelic frequency (%) | |
| Sample 1 | Sample 2 | |||
EGFR | L858R | 5.0% | 4.4% | 5.8% |
EGFR | T790M | 5.0% | 4.2% | 3.5% |
EGFR | ΔE746_A750 | 5.0% | 2.7% | 3.0% |
KRAS | A146T | 5.0% | 6.0% | 9.7% |
KRAS | G12D | 5.0% | 4.9% | 4.8% |
KRAS | G13D | 5.0% | 2.6% | 3.2% |
KRAS | Q61K | 5.0% | 5.4% | 4.6% |
PIK3CA | E545K | 5.0% | 6.7% | 6.0% |
Probe density in regions of 641 tumor-related genes are increased to ensure the mutation calling in tumor hotspot regions. Test results of AIExome® V3 – Tumor (Illumina NovaSeq 6000, PE150, ~500X) using gDNA reference standard (Gene-Well, cat. GW-OGTM800) showed higher sequencing depth of important hotspot regions.
| Product Name | Panel Number | Set | Cat. No |
| AIExome® Human Exome Panel V3 - Tumor | T600V1ST | 16 rxn | PT1009181 |
| 96 rxn | PT1009182 |
CN
